| Nov 13 |
3 US Penny Stocks With Market Caps Over $40M To Consider
|
| Nov 5 |
Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech
|
| Oct 29 |
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
|
| Sep 30 |
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
|
| Sep 23 |
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
|
| Sep 10 |
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
|
| Sep 9 |
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
|
| Aug 29 |
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
|
| Aug 27 |
Rallybio to Present at Upcoming Investor Conferences
|
| Aug 14 |
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
|
